Benzimidazole derivatives as selective proteine kinase inhibitors
US10202370B2 · kind B2 · utility
0Cited by
0References
8Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 20, 2014 |
| Grant date | Feb 12, 2019 |
| Priority date | — |
| Expiry date | Jan 3, 2035 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D417/12
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed are compounds of formula I or pharmaceutically acceptable salts thereof: Wherein n, R1, R2, R3, R4, R5, A, Q and X are as defined in the description. These compounds selectively modulate, regulate, and/or inhibit signal transduction mediated by certain native and/or mutant protein kinases implicated in a variety of human and animal diseases such as cell proliferative, metabolic, allergic, and degenerative disorders. More particularly, these compounds are potent and selective native and/or mutant c-kit inhibitors.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.